EGFR and head and neck squamous cell carcinoma: Despite the reported intrinsic and acquired resistance to EGFR‐targeting agents, interest in targeting EGFR for the treatment of HNSCC remains high, with new strategies, such as inhibitor combinations and novel irreversible or multitargeting inhibitors, currently being evaluated.